Scholarlink

Background <p>Androgen deprivation therapy (ADT) remains the standard of care for the treatment of advanced and metastatic prostate cancer (PC). However, in older patients, the choice of treatment must be made carefully, as they often have comorbidities and are at risk of potential side effects. Newer hormonal therapies (androgen receptor pathway inhibitors, ARPIs) have expanded the treatment spectrum, raising questions about optimal therapy for older patients.</p> Objective <p>This article provides an overview of the evidence-based use of ADT and ARPI in older patients, with a&#xa0;particular focus on relevant guideline recommendations and study results across different stages of prostate cancer. It also describes how individualized treatment decisions can be made in clinical practice.</p> Materials and methods <p>Selective literature review on ADT and ARPI in older patients. Data from relevant clinical trials, current evidence, and recommendations from international and national guidelines (e.g., EAU, S3) are considered.</p> Results <p>For metastatic hormone-sensitive prostate cancer (mHSPC), the combination of ADT and ARPI has proven beneficial, particularly for patients with a&#xa0;life expectancy of more than 1&#xa0;year and a&#xa0;good performance status. Network meta-analyses show that dual- and triple-agent therapies improve overall survival in older patients, while side effects increase.</p> Conclusion <p>The use of ADT + ARPI improves survival rates but requires a&#xa0;nuanced assessment of side effects and quality of life, particularly in very old patients. Geriatric assessment helps classify patients into different risk groups and plays a&#xa0;central role in treatment decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Indikation der antihormonellen Therapie (ADT) beim fortgeschrittenen Prostatakarzinom beim älteren Patienten

  • 期刊论文

  • 发表日期：

    2026年5月19日

查看全文
  • Martina Heller,
  • Stefanie Zschäbitz

摘要

Background

Androgen deprivation therapy (ADT) remains the standard of care for the treatment of advanced and metastatic prostate cancer (PC). However, in older patients, the choice of treatment must be made carefully, as they often have comorbidities and are at risk of potential side effects. Newer hormonal therapies (androgen receptor pathway inhibitors, ARPIs) have expanded the treatment spectrum, raising questions about optimal therapy for older patients.

Objective

This article provides an overview of the evidence-based use of ADT and ARPI in older patients, with a particular focus on relevant guideline recommendations and study results across different stages of prostate cancer. It also describes how individualized treatment decisions can be made in clinical practice.

Materials and methods

Selective literature review on ADT and ARPI in older patients. Data from relevant clinical trials, current evidence, and recommendations from international and national guidelines (e.g., EAU, S3) are considered.

Results

For metastatic hormone-sensitive prostate cancer (mHSPC), the combination of ADT and ARPI has proven beneficial, particularly for patients with a life expectancy of more than 1 year and a good performance status. Network meta-analyses show that dual- and triple-agent therapies improve overall survival in older patients, while side effects increase.

Conclusion

The use of ADT + ARPI improves survival rates but requires a nuanced assessment of side effects and quality of life, particularly in very old patients. Geriatric assessment helps classify patients into different risk groups and plays a central role in treatment decisions.